Method Article
* These authors contributed equally
This protocol presents the clinical efficacy of heat-sensitive moxibustion in treating chronic obstructive pulmonary disease (COPD) combined with insomnia and outlines the procedure for heat-sensitive moxibustion.
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern and a heterogeneous lung disease characterized by persistent, progressive airflow obstruction due to airway and/or alveolar abnormalities. COPD is associated with various comorbidities, including insomnia, which is a common underlying condition. Chronic insomnia exacerbates morbidity, increases hospitalization rates and healthcare costs, and reduces the quality of life in patients with COPD.
Heat-sensitive moxibustion is an emerging therapy that utilizes heat generated by ignited moxa materials. This technique involves suspending moxibustion over heat-sensitive acupoints to stimulate various sensations, such as heat penetration, expansion, transfer, local non-heat with distant heat, superficial non-heat with deep heat, and non-thermal sensations. These effects, along with meridian Qi conduction, enhance the therapeutic efficacy of moxibustion, making it a distinctive Chinese medicine therapy for insomnia. This study evaluated the efficacy of heat-sensitive moxibustion in patients with COPD and comorbid insomnia. The results demonstrated that heat-sensitive moxibustion significantly reduced Pittsburgh Sleep Quality Index (PSQI) and COPD Assessment Test (CAT) scores, indicating improvements in sleep quality and overall quality of life. Additionally, serum levels of interleukin-6 (IL-6) were decreased, while 5-hydroxytryptamine (5-HT) levels were increased, suggesting a potential mechanism underlying the observed therapeutic effects. This article provides a detailed protocol for standardizing the use of heat-sensitive moxibustion in the treatment of COPD with insomnia and presents clinical outcomes supporting its efficacy.
Chronic Obstructive Pulmonary Disease (COPD) is a significant global health concern. It is a heterogeneous lung disease characterized by persistent and progressive airflow obstruction due to abnormalities in the airways and/or alveoli. Clinical symptoms include coughing, sputum production, dyspnea, and chest tightness. The global prevalence of COPD among individuals aged 30-79 years has been reported to be 10.3%, with a prevalence of 8.6% in China1,2.
COPD is frequently associated with comorbid conditions, including cardiovascular disease, osteoporosis, and pulmonary hypertension. The presence of comorbidities increases the risk of morbidity and mortality, leading to a higher likelihood of hospitalization and increased healthcare costs. Furthermore, comorbidities significantly impact the clinical status and prognosis of patients with COPD, complicating disease management3,4.
Sleep disorders are a common consequence of COPD and often occur alongside nocturnal COPD symptoms, particularly cough and dyspnea. Studies indicate that approximately 40% of patients with COPD experience sleep disorders5, including obstructive sleep apnea (OSA), insomnia, and restless legs syndrome (RLS). The prevalence of OSA, RLS, and insomnia in patients with COPD has been reported to be 29.1%, 21.6%, and 29.5%, respectively6. The incidence of insomnia in patients with COPD is approximately three times higher than in the general population7. Additionally, hospitalized COPD patients experience an average reduction of 34 min of sleep per night and have a 22.5% lower probability of achieving normal sleep efficiency compared to those without COPD8.
A variety of traditional sedatives and hypnotics, including benzodiazepines, imidazopyridines, and, to a lesser extent, antidepressants, have been used to treat insomnia in COPD patients. While clinical trials suggest that these medications can be effective, their safety is not always assured9,10.
Moxibustion has been shown to stimulate meridian Qi through heat and bioactive substances produced during combustion, thereby regulating physiological functions, treating diseases, and promoting overall health. Contemporary research suggests that the thermal stimulation from moxibustion plays a key role in disease treatment. The heat applied to the dermal level enhances blood flow, optimizes microcirculation, and facilitates vasodilation11. Additionally, volatile oils released during the combustion of wormwood can have a calming effect on the brain, regulate neurotransmitter imbalances, and increase cerebral levels of 5-hydroxytryptamine (5-HT) and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA)12,13.
Heat-sensitive moxibustion is a novel therapeutic approach that differs from traditional moxibustion. It involves the application of moxa heat to heat-sensitive acupoints, offering notable benefits for the treatment of insomnia14. This article presents a demonstration of heat-sensitive moxibustion for treating insomnia in a patient with COPD.
The protocol was approved by the Ethics Committee of the Zigong First People's Hospital (No. Ethical (M) 2024-033). This was a before-and-after treatment controlled trial involving patients from the Hospital of Chengdu University of Traditional Chinese Medicine and the to Zigong First People's Hospital. Informed consent was obtained from all patients who participated in the study. The details of the reagents and equipment used are listed in the Table of Materials.
1. Patient assessment
2. Study design
3. Pre-operation preparation
4. Operating procedure
NOTE: Ensure that all practitioners involved in treatment delivery are certified acupuncturists with a minimum of one year of independent clinical experience. To ensure the accuracy and reproducibility of acupoint localization, all practitioners must complete a standardized training program before the study. This program should include (1) a comprehensive review of acupoint anatomy and localization techniques based on established textbooks, (2) hands-on practice sessions following a standardized protocol to ensure consistent technique application, and (3) a final assessment to confirm proficiency in acupoint identification. Additionally, a calibration test was conducted to evaluate inter-rater reliability, allowing only practitioners who achieved a Cohen's Kappa score of ≥0.8 to participate in the study. The treatment was conducted in accordance with the National Standard of the People's Republic of China for Technical Practice of Acupuncture and Moxibustion, Part 1: Moxibustion (GB/T 21709.1-2008)20, and the Standardized Manipulations of Heat-sensitive Moxibustion Therapy21.
5. Adverse event prevention and countermeasures
6. Efficacy evaluation
7. Data statistics and analysis
This protocol outlines a before-and-after controlled trial investigating the efficacy of heat-sensitive moxibustion in improving sleep quality and overall quality of life in patients with COPD-related insomnia. A total of 12 patients (Table 3) diagnosed with COPD and insomnia were included in the study and received heat-sensitive moxibustion treatment.
Analysis of individual and total scores before and after treatment, including sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, daytime dysfunction, and total PSQI scores, revealed a significant reduction in scores after treatment (P < 0.05). This suggests that heat-sensitive moxibustion effectively improves sleep quality (Table 4).
Regarding quality of life, a comparison of CAT total scores before and after treatment showed a significant decrease in CAT scores after treatment (P < 0.05), indicating that heat-sensitive moxibustion improves patients' overall quality of life (Table 5).
Additionally, serum analysis revealed that IL-6 expression levels were significantly lower after treatment, while 5-hydroxytryptamine levels were significantly higher compared to baseline (P < 0.05), further supporting the potential therapeutic effects of heat-sensitive moxibustion (Table 6).
Figure 1: Surgical equipment. (A) Surgical curved disc, (B) moxa sticks, (C) medical swabs, (D) lighter, (E) tweezers, (F) pliers, and (G) thermometer. Please click here to view a larger version of this figure.
Figure 2: Acupuncture Points and Localization. Diagram illustrating the locations of acupuncture points. Please click here to view a larger version of this figure.
Figure 3: Three-inch measurement chart. The second knuckle of the patient's finger is used to measure the transverse width of all four fingers, corresponding to a measurement of 3 cun. Please click here to view a larger version of this figure.
Figure 4: Meridian circulation moxibustion. The moxa stick is held about one-third of the way up and lit with a lighter. The lit end is positioned perpendicularly over the meridian, 2-3 cm from the skin. Moxibustion is applied at a steady speed along the meridian route, with each session lasting 2-3 min. The procedure is repeated until the skin appears flushed, accompanied by a sensation of warmth and heat. Please click here to view a larger version of this figure.
Figure 5: Sparrow pecking moxibustion. The moxa stick is held about one-third of the way up and lit with a lighter. The lit end is positioned vertically above the meridian, 2-3 cm from the skin. A vertical up-and-down movement, resembling a sparrow pecking, is used to apply moxibustion at a consistent rhythm. Please click here to view a larger version of this figure.
Figure 6: Circular moxibustion. The moxa stick is held about one-third of the way up and lit with a lighter. The lit end is positioned perpendicularly above the meridian, 2-3 cm from the skin. Moxibustion is applied by rotating the lit end of the moxa stick in a circular motion around the acupuncture point, with a radius of approximately 2.5 cm. Please click here to view a larger version of this figure.
Figure 7: Mild moxibustion. The moxa stick is held about one-third of the way up and lit with a lighter. The lit end is positioned perpendicularly to the meridian, 2-3 cm from the skin, and directed toward the acupuncture point to produce smoke at a consistent distance. Please click here to view a larger version of this figure.
Figure 8: Double-point gentle moxibustion. Gentle moxibustion is applied simultaneously to two heat-sensitive points. Please click here to view a larger version of this figure.
Syndrome of Chinese medicine |
Primary symptoms |
1. Wheezing, shortness of breath,worsened by physical exertion |
2. Fatigue, or spontaneous sweating, aggravated by movement |
3. Easy to catch a cold, malignant wind |
Secondary symptoms |
1. Soreness and weakness of the lower back and knees |
2. Tinnitus, dizziness, or facial weakness and lethargy |
3. Frequent urination, nocturnal enuresis, or coughing and drowning |
4. Pale tongue texture, white fur on the tongue, or a sunken or thin and weak pulse |
Table 1: Diagnostic criteria for Traditional Chinese Medicine differentiation of lung and kidney qi deficiency in patients with chronic obstructive pulmonary disease.
Number | Types of moxibustion sensation | Definition |
1 | Heat penetration | The heat generated by moxibustion penetrates from the skin surface at the application site directly into deeper tissues, potentially reaching thoracic or abdominal organs. |
2 | Heat expansion | The heat radiates outward from the application site, spreading to surrounding areas. |
3 | Heat transmission | The heat travels along a specific pathway from the application site to distant regions, potentially reaching the affected area of the disease. |
4 | Local non-heat with distant heat | The application site feels little to no heat, while distant areas from the site experience significant heat sensation. |
5 | Superficial non-heat with deep heat | The skin at the application site feels little to no heat, while deeper tissues or even thoracic and abdominal organs experience significant heat sensation. |
6 | Non-Thermal Sensations | Non-thermal sensations such as soreness, distension, pressure, heaviness, pain, numbness, or coldness may occur at or distant from the moxibustion site. |
Table 2: Types and definition of thermal moxibustion sensation.
Gender | Age (years) | FEV1/FVC(%) |
Female | 55 | 63.25 |
Male | 60 | 60 |
Male | 58 | 58 |
Male | 72 | 48 |
Male | 62 | 50.77 |
Female | 73 | 56.64 |
Male | 60 | 48.32 |
Male | 67 | 49.67 |
Female | 59 | 55 |
Male | 74 | 55 |
Female | 68 | 62 |
Table 3: Basic information of patients included in the study.
PSQI factors | Before | After | Mean±SD | 95% CI | P |
Sleep quality | 2.75±0.452 | 1.00±0.603 | -1.75±0.45 | -2.04, -1.46 | <0.05 |
Sleep latency | 2.75±0.452 | 1.25±0.452 | -1.5±0.67 | -1.93, -1.07 | <0.05 |
Sleep duration | 2.33±0.492 | 1.58±0.514 | -0.75±0.45 | -1.04, -0.46 | 0.04 |
Sleep efficiency | 1.16±0.937 | 0.25±0.621 | -0.91±0.67 | -1.34, -0.49 | 0.001 |
Sleep disorder | 1.50±0.522 | 1.083±0.288 | -0.42±0.51 | -0.74, -0.09 | 0.017 |
Daytime dysfunction | 2.25±0.452 | 1.50±0.522 | -0.75±0.45 | -1.04, -0.46 | <0.05 |
Total | 12.75±2.05 | 6.66±1.61 | -6.08±1.31 | -6.91, -5.25 | 0.003 |
Table 4: Individual and Total Pittsburgh Sleep Quality Index (PSQI) scores before and after treatment. The PSQI scores of 12 patients were lower before treatment. A paired t-test was used for comparison before and after treatment, showing a statistically significant difference (P < 0.05). This result indicates an improvement in sleep quality following treatment, N = 12.
CAT Score | Before | After | Mean±SD | 95% CI | P |
CAT total score | 28.8333±2.08167 | 25.6667±1.77525 | -3.17±0.83 | -3.70, -2.64 | <0.05 |
Table 5: COPD Assessment Test (CAT) scores before and after treatment. A comparison of CAT scores before and after treatment in 12 patients showed a decrease in scores. A paired t-test was used for self-controlled comparison, with results showing a statistically significant difference (P < 0.05), indicating an improvement in patients' quality of life, N = 12.
Serum Parameters Test | Before | After | Mean±SD | 95% CI | P |
Il-6 (pg/mL) | 9.7155±0.924 | 8.063±0.577 | -1.65±0.65 | -2.06, -1.24 | <0.05 |
5-HT (ng/mL) | 72.58±2.68 | 94.32±9.48 | -83.45±12.91 | -88.62, -78.28 | <0.05 |
Table 6: Expression levels of IL-6 and 5-HT before and after treatment. The expression levels of IL-6 were decreased, while those of 5-HT were increased after treatment. A statistically significant difference was observed (P < 0.05), suggesting an improvement in sleep quality, N = 12.
Insomnia in patients with COPD can be attributed to several factors, including frequent awakenings due to hypoxemia and hypercapnia during sleep36, nocturnal respiratory symptoms, and the use of COPD medications, which may affect sleep patterns. Additionally, anxiety and depression are significant contributors to insomnia. The prevalence of depression in COPD patients has been reported to be as high as 80%, while anxiety affects up to 74% of patients37,38. Studies also indicate that over 20% of COPD patients are prescribed antidepressant medications39.
The current pharmacological treatment for COPD-related insomnia primarily includes sedatives and antidepressants. However, these medications may have adverse effects on the respiratory system, including an increased risk of respiratory depression, respiratory failure, and mortality40,41,42.
Feishu (BL13) belongs to the foot Taiyang bladder meridian and serves as the back-shu point of the lungs. It is a crucial acupoint for treating lung diseases, as it helps relieve cough, resolve phlegm, tonify lung qi, and regulate lung meridian qi. According to Classical Evidence and Treatment, the lungs govern qi, while the kidneys serve as its foundation. Traditional Chinese Medicine considers the pathogenesis of stable COPD to be closely related to dysfunction in the lungs, spleen, and kidneys. Data mining has identified BL13, BL20, and BL23 as core acupoints for treating stable COPD23,24, and several clinical studies have demonstrated that stimulation of these points improves FEV1% in COPD patients43,44.
In traditional Chinese Medicine (TCM), insomnia is classified as a disorder of both sleep and wakefulness and is frequently observed as a concomitant symptom of COPD. The TCM clinical guidelines of the Insomnia Research Group (WHO/WPO)45 describe the pathogenesis of insomnia as resulting from disharmony between yin and yang, qi and blood, and disturbances in the five viscera. These imbalances lead to disruptions in mental stability and spiritual restlessness.
According to TCM theory, the five viscera -- the heart, liver, spleen, lungs, and kidneys -- are intricately linked to various physiological functions and mental activities. The acupoints Xinshu (BL15), Pishu (BL20), Feishu (BL13), and Shenshu (BL23) correspond to the dorsal acupoints of the heart, spleen, lungs, and kidneys, respectively. These back-shu points belong to the foot Taiyang bladder meridian and serve as external manifestations of the internal organs. Their stimulation can regulate visceral functions and enhance the body's vital energy (zheng qi). External TCM therapies targeting these acupoints have been shown to be effective in treating insomnia46,47.
Additionally, the acupoint Danshu (BL19), located on the back, is associated with the gallbladder meridian. The gallbladder and heart meridians are interrelated and functionally coordinated, both playing key roles in mental regulation and qi circulation. TCM theory suggests that treating the heart and gallbladder in combination helps balance hippocampal monoamine neurotransmitters, including 5-hydroxytryptamine (5-HT), and promotes hippocampal cell repair25. Therefore, moxibustion stimulation of Feishu, Xinshu, Danshu, Pishu, and Shenshu acupoints may enhance sleep quality and overall well-being in COPD patients.
Heat-sensitive moxibustion represents an innovative approach to moxibustion therapy, distinct from traditional techniques. This method, developed and refined by Professor Chen Rixin, is based on the clinical phenomenon of moxibustion-induced thermal sensitivity. Research indicates that in patients with diseases, the thermal sensitivity rate of acupoints is approximately 70%, significantly higher than the 10% observed in healthy individuals. Following recovery, the sensitivity rate declines to around 10%, suggesting a strong correlation between thermal sensitivity and disease states.
Professor Chen Rixin introduced the concept of "identification of sensitive moxibustion," emphasizing that clinical moxibustion should not only focus on selecting acupoints but also prioritize acupoints with heightened thermal sensitivity. This individualized approach tailors moxibustion treatment to each patient, aiming to eliminate heat-sensitive sensations and achieve the desired therapeutic desensitization48. Clinical studies have demonstrated the efficacy of heat-sensitive moxibustion, highlighting its superiority over traditional moxibustion techniques49. Previous research has shown that thermal moxibustion is effective in managing both insomnia and COPD14,50,51.
Melatonin, a neurohormone crucial for maintaining circadian rhythms, is regulated by 5-hydroxytryptamine (5-HT), a neurotransmitter involved in sleep modulation52,53. Studies have also indicated that sleep disorders are associated with elevated levels of interleukin-6 (IL-6)54. The present study found that heat-sensitive moxibustion increased 5-HT levels while reducing IL-6 expression, suggesting its potential as an effective therapy for improving sleep in patients with COPD-related insomnia. As an external therapy in traditional Chinese medicine, heat-sensitive moxibustion leverages the unique principles of Chinese Medicine, offering a promising treatment approach for COPD patients with insomnia. However, as this study is a small sample, pre-post self-controlled, single-center trial, its objectivity may be limited. Future research should incorporate a larger sample size and include control groups to minimize bias and enhance the reliability of findings.
The authors have nothing to disclose.
This research was supported by the 2022 "Tianfu Qingcheng Plan" Tianfu Science and Technology Leading Talents Project (Chuan Qingcheng No. 1090) and Sichuan Science and Technology Program (2023ZYD0050). The authors would like to thank Mr. Yi Zhu for participating in our study as a model.
Name | Company | Catalog Number | Comments |
Adobe Photoshop 2021 | Adobe Systems | ||
Forcep | Cofoe Medical Technology Co.,ltd. | Hunan Medical Device Registration Certificate: No.20160012 | |
IBM SPSS Statistics 25 | IBM | ||
Lighter | Ningbo Qiant Technology Co., Ltd | Chaofan-CF2 | |
Medical swabs | Cofoe Medical Technology Co.,ltd. | Hunan Medical Device Registration Certificate: No.20192140881 | |
Moxa sticks | Nanyang Xian Herb Pharmaceutical Co., Ltd | XC23T07019 | |
Surgical tray | Jiangsu Kangjian Medical Apparatus Co.,Ltd. | Medium Size | |
Thermometer | Cofoe Medical Technology Co.,ltd. | Hunan Medical Device Registration Certificate: No.20182070190 | |
Tweezer | Cofoe Medical Technology Co.,ltd. | Hunan Medical Device Registration Certificate: No.20180176 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved